RABISHIELD 250IU

Indications

• Autoimmune diseases
• Cancer treatment
• Infectious diseases
• Transplant rejection prevention
• Allergy treatment

Dosage

Children: Dosage varies based on the specific antibody and condition being treated; refer to specific product guidelines for appropriate dosing.

Adults: Dosage varies based on the specific antibody and condition being treated; refer to specific product guidelines for appropriate dosing.

Mechanism of action

Antibodies exert their effects through several mechanisms. They can neutralize pathogens by binding to their surface, preventing them from entering or infecting cells. They also mark pathogens for destruction by immune cells, a process known as opsonization. Furthermore, antibodies can activate the complement system, leading to lysis of target cells, and can mediate antibody-dependent cellular cytotoxicity (ADCC) by recruiting immune effector cells.

Pharmacodynamics

The pharmacodynamics of antibodies is characterized by their affinity and specificity for antigens. The binding of an antibody to its target can trigger various immune responses, including phagocytosis by macrophages, activation of the complement pathway, and stimulation of cytotoxic T cells. The effectiveness of an antibody response is influenced by factors such as the concentration of the antibody, the presence of other immune modulators, and the nature of the antigen.

Pharmacokinetics

Antibodies have a complex pharmacokinetic profile. They are typically administered intravenously or subcutaneously, and their distribution is influenced by factors like size and charge. Antibodies have a long half-life, often ranging from several days to weeks, due to their recycling by the neonatal Fc receptor (FcRn). They are metabolized primarily in the liver and spleen, with elimination occurring through proteolytic degradation rather than renal excretion.

Adverse effects

• Infusion reactions
• Allergic reactions
• Increased risk of infections
• Cytopenias (such as thrombocytopenia or leukopenia)
• Autoimmune phenomena

Precautions

• Monitor for infusion-related reactions during administration
• Assess for previous hypersensitivity to monoclonal antibodies
• Use with caution in patients with a history of infections
• Consider the risk of immunosuppression
• Monitor blood counts regularly

Pregnancy

Safety in pregnancy varies by specific antibody; consult relevant studies and guidelines for specific immunoglobulins.

Breast-feeding

Generally considered safe, but consult specific guidelines for individual antibodies.

Storage

Store in a refrigerator at 2 to 8 degrees Celsius. Do not freeze. Protect from light.

Formulations

• Intravenous infusion
• Subcutaneous injection
• Intramuscular injection

Dosage

Children: Dosage for human-derived biological products in pediatrics should be determined based on specific product guidelines and the clinical context.

Adults: Dosage for human-derived biological products varies widely. Refer to specific product information for appropriate dosing.

Mechanism of action

Human physiology is governed by complex biological systems involving various cellular and molecular pathways. The mechanisms of action for human-derived biological products vary widely depending on the specific context, including immune response, hormonal regulation, and metabolic processes.

Pharmacodynamics

Pharmacodynamics in humans involves the interaction of drugs with biological systems, resulting in therapeutic effects. This includes receptor binding, signal transduction, and physiological responses. The effects are influenced by genetic factors, existing health conditions, and concurrent medications.

Pharmacokinetics

Pharmacokinetics in humans involves the absorption, distribution, metabolism, and excretion (ADME) of substances. Factors such as age, sex, body weight, and organ function can significantly influence these processes. Drug absorption may occur via oral, intravenous, or other routes, while distribution depends on blood flow and tissue permeability. Metabolism typically occurs in the liver, and excretion primarily takes place through the kidneys.

Pregnancy

There is no specific information available; consult local guidelines.

Breast-feeding

There is no specific information available; consult local guidelines.

Storage

Store in a cool, dry place away from direct sunlight.

Indications

• Cancer treatment (e.g., breast cancer, lymphoma)
• Autoimmune diseases (e.g., rheumatoid arthritis, multiple sclerosis)
• Infectious diseases (e.g., COVID-19)
• Transplant rejection prevention

Dosage

Children: Refer to the BNF for Children for appropriate dosing guidelines for paediatric patients.

Adults: Refer to specific monoclonal antibody prescribing information in the BNF for recommended dosages based on the condition being treated.

Mechanism of action

Monoclonal antibodies work by binding to specific proteins (antigens) on the surface of cells. This binding can neutralize the target, mark it for destruction by other immune cells, or block signals that promote cell growth. The precise mechanism of action varies depending on the specific monoclonal antibody and its target, but generally involves modulation of immune responses or direct inhibition of pathological processes.

Pharmacodynamics

The pharmacodynamics of monoclonal antibodies involve their interaction with target antigens, which leads to various biological responses including activation of immune effector functions such as antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct inhibition of cellular signaling pathways. The effects can vary widely based on the characteristics of the antibody and the target antigen.

Pharmacokinetics

Monoclonal antibodies typically have long half-lives due to their large molecular size, which limits their renal clearance. They are mainly eliminated through proteolytic degradation in the reticuloendothelial system. Their distribution volume is usually large due to their ability to bind to tissues and cells. The pharmacokinetic profile can be influenced by factors such as target antigen expression, antibody format, and patient-specific factors including body weight and disease state.

Interactions

• abatacept: Severe (increases risk of generalised infection, possibly life-threatening)
• anakinra: Severe (increases risk of generalised infection, possibly life-threatening)
• anthracyclines: Severe (increases risk of cardiotoxicity)
• filgotinib: Severe (increases risk of immunosuppression)
• fingolimod: Severe (increases risk of generalised infection, possibly life-threatening)
• normal immunoglobulin: Severe (affects effects)
• ozanimod: Severe (increases risk of generalised infection, possibly life-threatening)
• siponimod: Severe (increases risk of generalised infection, possibly life-threatening)
• vemurafenib: Severe (increases risk of hepatotoxicity)
• aminophylline: Moderate (decreases exposure)

Pregnancy

Safety in pregnancy has not been established. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether monoclonal antibodies are excreted in human milk. Caution should be exercised when administering to a nursing mother.

Storage

Store at 2 to 8 degrees Celsius. Do not freeze. Protect from light.

Indications

• Rabies prevention in individuals at high risk of exposure
• Post-exposure prophylaxis following potential rabies exposure
• Vaccination for travelers to endemic regions

Dosage

Children: Refer to the BNF for Children for specific dosing recommendations for pediatric patients.

Adults: Refer to the BNF for specific dosing guidelines, as it varies based on exposure risk and vaccination history.

Mechanism of action

The rabies vaccine works by stimulating the immune system to produce antibodies against the rabies virus. This is achieved through the introduction of inactivated or attenuated virus particles, which mimic the infection without causing the disease. The immune response generated helps to prevent the virus from causing illness upon subsequent exposure.

Pharmacodynamics

The rabies vaccine induces an adaptive immune response, leading to the production of neutralizing antibodies specific to the rabies virus. This immune memory protects against future infections. The vaccine is typically administered in a series of doses to ensure adequate immune response and long-term protection.

Pharmacokinetics

The pharmacokinetics of the rabies vaccine involve absorption at the injection site, followed by systemic distribution of the antigens. The onset of immunity generally occurs within two weeks after the initial vaccination, with peak antibody levels typically reached within one to two months. The duration of immunity can vary, necessitating booster doses in certain populations.

Interactions

• chloroquine+rabiesvaccine: Severe (decreases efficacy)

Pregnancy

Rabies vaccination is generally considered safe during pregnancy. However, the risks and benefits should be carefully evaluated.

Breast-feeding

Rabies vaccine is not known to cause any adverse effects in breastfeeding. However, consult with a healthcare provider for individual assessments.

Storage

Store the rabies vaccine in a refrigerator at 2-8 degrees Celsius. Do not freeze.